Mirabegron available to treat overactive bladder

March 2013
British Journal of Hospital Medicine (17508460);Mar2013, Vol. 74 Issue 3, p129
Academic Journal
The article reports that use of a first-in-class once-daily oral beta 3 adrenoceptor agonist Mirabegron in different treatments.


Related Articles

  • Presente y futuro del tratamiento farmacol�gico de la vejiga hiperactiva. Mu�oz G�lligo, E.; Garc�a Garc�a-Porrero, A.; Masero Casasola, A. R.; Mu�oz Garrido, F. // Suelo P�lvico;2012, Vol. 8 Issue 3, p64 

    The overactive bladder syndrome has a complex physiopathological basis, which implies muscular and neural systems and a complex array of molecular intermediaries. In fact, in our days the pharmacological treatment, based on anticholinergics drugs, is not effective in a great proportion of...

  • Mirabegron -- promising new drug for overactive bladder syndrome. Rigby, Debbie // Australian & New Zealand Continence Journal;Winter2015, Vol. 21 Issue 2, p40 

    The article discusses the potential therapeutic use of antimuscarinic agent Mirabegron in treating patients with urinary incontinence (UI) and overactive bladder (OAB) syndrome. Information regarding the drugs adverse health effects, prescribed dosage, and tolerance, are discussed. The article...

  • Mirabegron: a guide to its use in overactive bladder syndrome in the EU. Sanford, Mark; Lyseng-Williamson, Katherine // Drugs & Therapy Perspectives;Apr2015, Vol. 31 Issue 4, p107 

    Mirabegron (Betmiga™), a β-adrenergic receptor agonist, is a useful option for the treatment of overactive bladder syndrome. In clinical trials in this patient population, oral mirabegron 50 mg once daily significantly reduced incontinence and micturition episodes, consistently reduced...

  • Overactive Bladder and the β-Adrenoceptor Agonists: Current Strategy and Future Prospects. Giarenis, Ilias; Robinson, Dudley; Cardozo, Linda // Drugs;Oct2015, Vol. 75 Issue 15, p1707 

    Overactive bladder (OAB) is a clinical syndrome describing the symptom complex of urgency, with or without urgency incontinence, and is usually associated with frequency and nocturia. It is a common, under-diagnosed and therefore under-treated condition that can have a detrimental effect on...

  • A Case-Based Approach for Overactive Bladder to Evaluate and Implement Successful Treatment Strategies. Ellsworth, Pamela // Journal of Managed Care Medicine;2014, Vol. 17 Issue 1, p10 

    No abstract available.

  • The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Wagg, Adrian; Cardozo, Linda; Nitti, Victor W.; Castro-Diaz, David; Auerbach, Stephen; Blauwet, Mary Beth; Siddiqui, Emad // Age & Ageing;Sep2014, Vol. 43 Issue 5, p666 

    Introduction: mirabegron is a β3-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB). As the prevalence of OAB increases with age, a prospective subanalysis of individual and pooled efficacy and tolerability data from three 12-week, randomised, Phase III...

  • Pharmacology treatment of OAB in adults. Everaert, K. // Australian & New Zealand Continence Journal;Summer2015, Vol. 21 Issue 4, p118 

    The article presents an abstract on pharmacology treatment of overactive bladder in adults and mentions topics such as urinary bladder, anticholinergics, and lower urinary tract symptoms.

  • Mirabegron: A Review of Its Use in Patients with Overactive Bladder Syndrome. Sanford, Mark // Drugs;2013, Vol. 73 Issue 11, p1213 

    Mirabegron (YM178, Myrbetriq™, Betanis, Betmiga™) is a β-adrenergic receptor agonist approved in several countries for the symptomatic treatment of adults with overactive bladder syndrome. In three 12-week, randomized, double-blind, placebo-controlled, multinational trials in...

  • Still cause for concern. Tattersfield, A.E. // BMJ: British Medical Journal (International Edition);9/24/94, Vol. 309 Issue 6957, p794 

    Focuses on the use of beta agonist on patients with asthma in the Great Britain. Mortality rate in the year 1960s and 1970s; Implication of high dosage of beta agonists on mortality rate from asthma; Suggestion of the morbidity study on the tolerance of beta agonist among asthma patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics